$3.21 0.00 (0.00%)

NRX Pharmaceuticals, Inc. Common Stock (NRXP)

NRX Pharmaceuticals, Inc. (NRXP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders. The company aims to address unmet medical needs through clinical development and commercialization of novel pharmaceutical products.

🚫 NRX Pharmaceuticals, Inc. Common Stock does not pay dividends

Company News

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
Benzinga • Globe Newswire • October 20, 2025

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, acquired a strategic interest in Cohen and Associates, a premier interventional psychiatry clinic in Florida. Dr. Rebecca Cohen was appointed as HOPE's Medical Director, bringing expertise in TMS and psychiatric treatments.

NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
Zacks Investment Research • Zacks Equity Research • April 25, 2024

The latest trading day saw NRx Pharmaceuticals, Inc. (NRXP) settling at $3.14, representing a +0.64% change from its previous close.

3 Penny Stocks Under $3 To Watch Right Now
PennyStocks • J. Phillip • December 19, 2023

Penny stocks under $3 to watch this week. The post 3 Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Shares of Bausch Health Companies Dropped 54.4% This Week
The Motley Fool • [email protected] (Jim Halley) • July 28, 2022

A patent-court loss sent investors scurrying to the exits.

NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLifeâ„¢ Covid-19 Investigational Vaccine
GlobeNewswire Inc. • NeuroRx, Inc. • February 11, 2022

RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the Israel Institute for Biological Research, who spoke at the Eli Hurvitz Institute for Strategic Management of Tel Aviv University. His remarks were summar...